Skip to main content
. 2018 May 8;9(35):24081–24096. doi: 10.18632/oncotarget.25300

Table 3. Overall distribution of the KRAS, NRAS, BRAF and TP53 gene mutations detected by next generation sequencing in the 87 colorectal cancer patients analyzed.

Gene status N. of cases (%) Exon location Mutation (N. of cases)
KRAS
 Wild type 63 (72%)
 Mutated 24 (28%)
Exon 2 G12D(7), G12V(5), G12A(4), G12S(1), G13D(2)
Exon 3 Q61H(1), Q61L(1)
Exon 4 A146P(1), A146T(1), K147E(1)
NRAS
 Wild type 86 (99%)
 Mutated 1 (1%)
Exon 3 Q61K(1)
BRAF
 Wild type 81 (93%)
 Mutated 6 (7%)
Exón 15 V600E (6)
TP53
 Wild type 58 (66%)
 Mutated 29 (33%)
Exon 4 L111R (1), G112del (1)
Exon 5 C135F (1), P152AfsTer14 (1), R156H (1), R158C (1), V173L (1), R175H (3), H178PfsTer47 (1), c.376-2A>G splice (1)
Exon 6 Q192* (1), R196* (1), L201GfsTer47 (1), S215R (1).
Exon 7 R248W (2), R248Q (1), C275Y (1), N247I (1), T253PfsTer92 (1)
Exon 8 R282W (3), R273C (1), C277VfsTer68 (1), V272M (1)
Exon 10 S366A (1)

Results expressed as number of cases (percentage).